ArticleInternational journal of molecular medicine2019

Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.

Ke Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.